Traditional companies focus their innovative efforts on the discovery of new drugs that save and improve lives. Apobiologix sees a need to go further: to create sustainable health care that doesn't sacrifice quality or patient support. That's why biosimilars also require innovation.
Apobiologix is focused on the development of biosimilars that combine the quality and value you need with the level of comprehensive support you expect.
Because at Apobiologix, we don't believe that innovation stops at invention.
Apobiologix is a company with over 10 years of biosimilar development history and over 5 years of combined biosimilar post-marketing experience in Canada and the EU.
Apobiologix successfully launched Grastofil in Canada in early 2016. Grastofil was the first biosimilar filgrastim approved by Health Canada for the same indications of use as the reference biologic. Grastofil has been widely adopted by payers across the country – both public and private. Patients prescribed Grastofil are supported by Apobiologix's ANSWERS™ program (patient support program). In 2018, Apobiologix's Lapelga became the first pegfilgrastim biosimilar to receive approval from Health Canada. This is the first approval of biosimilar pegfilgrastim in Canada and in the world.
2400 North Commerce Parkway,
Weston, Florida 33326
Grastofil® is a registered trademark of Apotex Technologies Inc.
Lapelga™ is a trademark of Apotex Technologies Inc.
ANSWERS™ is a trademark of Apotex Technologies Inc.
Neupogen® and Neulasta® are registered trademarks of Amgen.